FRAS1 Inhibitors
Chemical inhibitors of FRAS1 can function through various biochemical and cellular pathways to achieve functional inhibition of the protein. WZ4002, an EGFR inhibitor, can block the epithelial-to-mesenchymal transition (EMT) process in which FRAS1 is implicated, thus stabilizing epithelial characteristics and preventing the transition to a mesenchymal state where FRAS1 is functionally active. Similarly, PF-562271, by inhibiting focal adhesion kinase (FAK), impairs cellular migration processes, consequently inhibiting FRAS1's role in cell movement and extracellular matrix interactions. GM6001, a matrix metalloproteinase inhibitor, can prevent the extracellular matrix remodeling required for FRAS1's role in tissue repair and development, thereby inhibiting its function. DAPT, by inhibiting gamma-secretase, impedes Notch signaling, which is associated with FRAS1 in development and cell differentiation, and can thus inhibit FRAS1's functionality. SB431542 targets the TGF-beta receptor, disrupting a pathway integral to tissue development and repair where FRAS1 operates, which results in functional inhibition of FRAS1.
LY294002 disrupts PI3K/Akt signaling, a pathway regulating cell adhesion and migration, where FRAS1 has a role; therefore, this inhibitor can functionally inhibit FRAS1. U0126, a MEK inhibitor, prevents ERK pathway activation, which is essential for signaling and development processes involving FRAS1, leading to its functional inhibition. SP600125 inhibits the JNK signaling cascade, involved in stress response processes with which FRAS1 is associated, thereby inhibiting FRAS1's function. Y-27632, a ROCK inhibitor, impacts the Rho/ROCK pathway crucial for cytoskeletal organization; since FRAS1 is involved in this process, this inhibition can alter cytoskeletal dynamics, leading to the functional inhibition of FRAS1. AG490 disrupts JAK/STAT signaling, affecting cell communication processes in which FRAS1 is involved, thus functionally inhibiting FRAS1. PP2 inhibits Src family tyrosine kinases that participate in several signaling pathways including those involving FRAS1, leading to its functional inhibition. Lastly, NSC23766 inhibits Rac1 GTPase, which regulates actin cytoskeleton and cell adhesion, processes in which FRAS1 is functionally involved, thus NSC23766 can inhibit the cellular functions mediated by FRAS1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
WZ4002 is an EGFR inhibitor that can block the epithelial-to-mesenchymal transition (EMT) process. Since FRAS1 has been implicated in EMT, WZ4002 can indirectly inhibit FRAS1 by stabilizing epithelial characteristics and preventing the mesenchymal transition where FRAS1 is involved. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $77.00 $270.00 | 55 | |
GM6001 is a matrix metalloproteinase (MMP) inhibitor. MMPs facilitate extracellular matrix remodeling, which is a process that FRAS1 is involved in, particularly in tissue repair and development. Inhibition of MMPs can prevent the matrix remodeling required for FRAS1's functional role. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT is a gamma-secretase inhibitor that can inhibit Notch signaling. Since FRAS1 has been linked to processes that are modulated by Notch signaling, such as development and cell differentiation, DAPT can indirectly inhibit FRAS1 by impeding Notch pathway-related events. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is an inhibitor of the TGF-beta receptor. TGF-beta signaling plays a role in tissue development and repair, processes where FRAS1 is active. Inhibition of this receptor can disrupt the TGF-beta pathway, and consequently the functional activities of FRAS1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can disrupt the PI3K/Akt pathway. Since FRAS1 is involved in cellular processes that are regulated by PI3K signaling, such as cell adhesion and migration, inhibiting this pathway can functionally inhibit the activities of FRAS1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can inhibit the JNK signaling cascade. FRAS1 is associated with cellular processes that are regulated by stress-activated pathways like JNK, so inhibition of this pathway can lead to functional impairment of FRAS1. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that impairs the Rho/ROCK pathway. The Rho/ROCK pathway is involved in cytoskeletal organization, a process that FRAS1 is also involved in. Inhibiting ROCK can lead to cytoskeletal changes that functionally inhibit FRAS1. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $84.00 $329.00 $223.00 $87.00 | 35 | |
AG490 is a JAK2 inhibitor that can disrupt the JAK/STAT signaling pathway. FRAS1 has been shown to be involved in cell communication processes that are regulated by the JAK/STAT pathway, so AG490 can functionally inhibit FRAS1 by disrupting this signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family tyrosine kinase inhibitor. As FRAS1 is involved in signaling pathways that include the action of Src kinases, inhibition of these kinases by PP2 can lead to functional inhibition of FRAS1-related activities. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC23766 is an inhibitor of the Rac1 GTPase. Rac1 is involved in regulating the actin cytoskeleton and cell adhesion, processes in which FRAS1 has a functional role. Inhibition of Rac1 by NSC23766 can thus inhibit the cellular functions mediated by FRAS1. | ||||||